STE · 8-K · 20260805PR053412
Guidance / Outlook
STERIS plc · 2026-08-05 · Importance 85 · Surprise 76 · No source text
STERIS reiterated its fiscal 2027 revenue and earnings guidance, including reported revenue growth of 7% to 8%, constant-currency organic revenue growth of 6% to 7%, and adjusted diluted EPS of $11.10 to $11.30. Capital-expenditure guidance increased to approximately $450 million from $375 million, reflecting the North Carolina formulated-chemistries manufacturing Center of Excellence investment. Fiscal 2027 free-cash-flow guidance decreased to approximately $800 million from $850 million because of the higher capital expenditures, partly offset by stronger-than-expected first-quarter cash flow.
Key facts
- Adjusted net income from continuing operations per diluted share for FY 2027 is estimated at $11.10 - $11.30, with net income from continuing operations per diluted share estimated at $8.92 - $9.12 and adjustments for amortization of acquired intangible assets of 2.08 and restructuring charges of 0.07. source
- Adjusted earnings per diluted share for fiscal 2027 are anticipated to be in the range of $11.10 to $11.30, unchanged from prior expectations. source
- The Company is reiterating prior guidance for fiscal 2027 as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | +6.4% | The Company is reiterating prior guidance for fiscal 2027 as reported revenue growth of 7-8% and constant currency organic revenue growth… |
| net_income | unclear | committed | — | Adjusted net income from continuing operations per diluted share for FY 2027 is estimated at $11.10 - $11.30, with net income from… |